Homology Medicines to Participate in Upcoming Investor Conferences
03 March 2022 - 11:30PM
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines
company, announced today participation at the following virtual
investor conferences:
- Cowen 42nd Annual Health Care Conference:
- Corporate Panel Discussion – Gene Editing: March 8 at 12:50
p.m. ET
- Oppenheimer 32nd Annual Healthcare Conference:
- Fireside Chat: March 16 at 1:20 p.m. ET
- H.C. Wainwright Gene Therapy and Gene Editing Conference:
- Available on-demand March 30 at 7:00 a.m. ET
The webcast presentations from the investor conferences will be
accessible on Homology’s website in the Investors section, and the
webcast replays will be available on the website for 90 days
following the presentations.
About Homology Medicines, Inc.Homology
Medicines, Inc. is a clinical-stage genetic medicines company
dedicated to transforming the lives of patients suffering from rare
diseases by addressing the underlying cause of the disease.
Homology’s clinical programs include HMI-102, an investigational
gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene
editing candidate for PKU; and HMI-203, an investigational gene
therapy for Hunter syndrome. Additional programs focus on
metachromatic leukodystrophy (MLD), paroxysmal nocturnal
hemoglobinuria (PNH) and other diseases. Homology’s proprietary
platform is designed to utilize its family of 15 human
hematopoietic stem cell-derived adeno-associated virus vectors
(AAVHSCs) to precisely and efficiently deliver genetic medicines in
vivo through a gene therapy or nuclease-free gene editing modality,
as well as to deliver one-time gene therapy to produce antibodies
throughout the body through the GTx-mAb platform. Homology has a
management team with a successful track record of discovering,
developing and commercializing therapeutics with a focus on rare
diseases. Homology believes its initial clinical data and
compelling preclinical data, scientific and product development
expertise, internal manufacturing capabilities and broad
intellectual property position Homology as a leader in genetic
medicines. For more information, visit
www.homologymedicines.com.
Company ContactsTheresa McNeelyChief
Communications Officer and Patient
Advocatetmcneely@homologymedicines.com781-301-7277
Media Contact:Cara Mayfield Vice President,
Patient Advocacy and Corporate Communications
cmayfield@homologymedicines.com 781-691-3510
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Apr 2024 to May 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From May 2023 to May 2024